Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Hepatology Reports
Published in: Current Hepatology Reports 1/2024

Open Access 22-02-2024 | Hepatocellular Carcinoma

Indication of Liver Transplant for HCC: Current Status and Future Directions

Authors: Julian K. Horwitz, Vatche G. Agopian

Published in: Current Hepatology Reports | Issue 1/2024

Login to get access

Abstract

Purpose of Review

Liver transplantation remains the gold-standard treatment for cirrhotic patients with early stage, surgically unresectable hepatocellular carcinoma (HCC). In this review, we describe the current state of liver transplantation (LT) for HCC.

Recent Findings

We review recent advances in expanded indications for LT, diagnostics with liquid biopsy and biomarkers, and the emerging role of immunotherapy in this patient population.

Summary

Although the shortage of liver allografts necessitates a restrictive HCC selection policy, future advances in patient selection, liquid biopsy technologies and systemic therapies have the potential to improve access to liver transplantation even in patients with expanded indications, without compromising on post-transplant outcomes.
Literature
1.
Van Thiel DH, Carr B, Iwatsuki S, Selby RR, Fung JJ, Starzl TE. The 11-year Pittsburgh experience with liver transplantation for hepatocellular carcinoma: 1981–1991. J Surg Oncol Suppl. 1993;3:78–82.PubMedPubMedCentralCrossRef
2.
3.
Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol. 2017;14(4):203–17.PubMedCrossRef
4.
Agopian VG, Harlander-Locke M, Zarrinpar A, Kaldas FM, Farmer DG, Yersiz H, Finn RS, Tong M, Hiatt JR, Busuttil RW. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients. J Am Coll Surg. 2015Apr;220(4):416–27.PubMedCrossRef
5.•
Kwong AJ, Ebel NH, Kim WR, et al. OPTN/SRTR 2021 annual data report: liver. Am J Transplant. 2023;23(2 Suppl 1):S178–263. Most up-to-date U.S. liver transplantation demographics and outcomes data.
6.
Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400(10360):1345–62.PubMedCrossRef
7.
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.PubMedCrossRef
8.
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7–33.PubMedCrossRef
9.
Muhammad H, Tehreem A, Ting PS, et al. Hepatocellular carcinoma and the role of liver transplantation: a review. J Clin Transl Hepatol. 2021;9(5):738–48.PubMedPubMedCentral
10.
Maucort-Boulch D, de Martel C, Franceschi S, Plummer M. Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide. Int J Cancer. 2018;142(12):2471–7.PubMedCrossRef
11.
Romano A, Angeli P, Piovesan S, et al. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study. J Hepatol. 2018;69(2):345–52.PubMedCrossRef
12.
van der Meer AJ, Feld JJ, Hofer H, et al. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. J Hepatol. 2017;66(3):485–93.PubMedCrossRef
13.
14.
Sarasin FP, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med. 1996;101(4):422–34.PubMedCrossRef
15.
Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med. 2014;11(4):1–20.CrossRef
16.••
Singal AG, Llovet JM, Yarchoan M, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma [published online ahead of print, 2023 May 22]. Hepatology. 2023;https://​doi.​org/​10.​1097/​HEP.​0000000000000466​. Revised American Association for the Study of Liver Diseases (AASLD) treatment guidelines for HCC.
17.
Chernyak V, Fowler KJ, Kamaya A, et al. Liver Imaging Reporting and Data System (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients. Radiology. 2018;289(3):816–30.PubMedCrossRef
18.
About-Alfa GK, Pawlik TM, Shindoh J, et al. Liver. In: Amin MB, editor., et al., AJCC cancer staging manual. 8th ed. Chicago: Springer; 2017. p. 287.
19.••
Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76(3):681–93. Updated Barcelona Clinic Liver Cancer (BCLC) staging and treatment guidelines.
20.
Pinna AD, Yang T, Mazzaferro V, et al. Liver transplantation and hepatic resection can achieve cure for hepatocellular carcinoma. Ann Surg. 2018;268:868–75.PubMedCrossRef
21.
Berzigotti A, Reig M, Abraldes JG, Bosch J, Bruix J. Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. Hepatology. 2015;61:526–36.PubMedCrossRef
22.
Rahbari NN, Garden OJ, Padbury R, et al. Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery. 2011;149(5):713–24.PubMedCrossRef
23.
Aufhauser DD, Sadot E, Murken DR, Eddinger K, Hoteit M, Abt PL, et al. Incidence of occult intrahepatic metastasis in hepatocellular carcinoma treated with transplantation corresponds to early recurrence rates after partial hepatectomy. Ann Surg. 2018;267(5):922–8.PubMedCrossRef
24.
Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg. 2015;261(5):947–55.PubMedCrossRef
25.
Halazun KJ, Najjar M, Abdelmessih RM, et al. Recurrence after liver transplantation for hepatocellular carcinoma: a new MORAL to the story. Ann Surg. 2017;265(3):557–64.PubMedCrossRef
26.
Sogawa H, Shrager B, Jibara G, Tabrizian P, Roayaie S, Schwartz M. Resection or transplant-listing for solitary hepatitis C-associated hepatocellular carcinoma: an intention-to-treat analysis. HPB. 2013;15(2):134–41.PubMedCrossRef
27.
Zheng J, Chou JF, Gönen M, et al. Prediction of hepatocellular carcinoma recurrence beyond milan criteria after resection: validation of a clinical risk score in an international cohort. Ann Surg. 2017;266(4):693–701.PubMedCrossRef
28.
Guerrini GP, Esposito G, Olivieri T, et al. Salvage versus primary liver transplantation for hepatocellular carcinoma: a twenty-year experience meta-analysis. Cancers (Basel). 2022;14(14):3465.PubMedCrossRef
29.
Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–9 (optn).PubMedCrossRef
30.
Mazzaferro V, Bhoori S, Sposito C, et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl. 2011;17(Suppl 2):S44–57.PubMedCrossRef
31.
Heimbach JK. Evolution of liver transplant selection criteria and U.S. allocation policy for patients with hepatocellular carcinomA. Semin Liver Dis. 2020;40(4):358–64.PubMedCrossRef
32.
Sharma P, Harper AM, Hernandez JL, et al. Reduced priority MELD score for hepatocellular carcinoma does not adversely impact candidate survival awaiting liver transplantation. Am J Transplant. 2006;6(08):1957–62.PubMedCrossRef
33.
Halazun KJ, Patzer RE, Rana AA, et al. Standing the test of time: outcomes of a decade of prioritizing patients with hepatocellular carcinoma, results of the UNOS natural geographic experiment. Hepatology. 2014;60(06):1957–62.PubMedCrossRef
34.
Shaikh A, Goli K, Rich NE, et al. Early impact of MMaT-3 policy on liver transplant waitlist outcomes for hepatocellular carcinoma. Transplant Direct. 2022;8(5):e1313 (Published 2022 Apr 12).PubMedPubMedCentralCrossRef
35.
Lingiah VA, Niazi M, Olivo R, Paterno F, Guarrera JV, Pyrsopoulos NT. Liver transplantation beyond Milan criteria. J Clin Transl Hepatol. 2020;8:69–75.PubMedPubMedCentralCrossRef
36.
Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33(6):1394–403.PubMedCrossRef
37.
Ince V, Sahin TT, Akbulut S, Yilmaz S. Liver transplantation for hepatocellular carcinoma: historical evolution of transplantation criteria. World J Clin Cases. 2022;10(29):10413–27.PubMedPubMedCentralCrossRef
38.
Yao FY, Mehta N, Flemming J, et al. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology. 2015;61(6):1968–77.PubMedCrossRef
39.
Kardashian A, Florman SS, Haydel B, Ruiz RM, Klintmalm GB, Lee DD, Taner CB, Aucejo F, Tevar AD, Humar A, Verna EC, Halazun KJ, Chapman WC, Vachharajani N, Hoteit M, Levine MH, Nguyen MH, Melcher ML, Langnas AN, Carney CA, Mobley C, Ghobrial M, Amundsen B, Markmann JF, Sudan DL, Jones CM, Berumen J, Hemming AW, Hong JC, Kim J, Zimmerman MA, Nydam TL, Rana A, Kueht ML, Fishbein TM, Markovic D, Busuttil RW, Agopian VG. Liver transplantation outcomes in a U.S. multicenter cohort of 789 patients with hepatocellular carcinoma presenting beyond Milan criteria. Hepatology. 2020;72(6):2014–28.PubMedCrossRef
40.
Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10(1):35–43.PubMedCrossRef
41.
Toso C, Meeberg G, Hernandez-Alejandro R, et al. Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: a prospective validation. Hepatology. 2015;62(1):158–65.PubMedCrossRef
42.
Sapisochin G, Goldaracena N, Laurence JM, et al. The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: a prospective validation study. Hepatology. 2016;64(6):2077–88.PubMedCrossRef
43.
Kaido T, Ogawa K, Mori A, et al. Usefulness of the Kyoto criteria as expanded selection criteria for liver transplantation for hepatocellular carcinoma. Surgery. 2013;154(5):1053–60.PubMedCrossRef
44.
Vibert E, Schwartz M, Olthoff KM. Advances in resection and transplantation for hepatocellular carcinoma. J Hepatol. 2020;72(2):262–76.PubMedCrossRef
45.
Mazzaferro V, Sposito C, Zhou J, et al. Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma. Gastroenterology. 2018;154(1):128–39.PubMedCrossRef
46.
Norman JS, Li PJ, Kotwani P, Shui AM, Yao F, Mehta N. AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation. J Hepatol. 2023Dec;79(6):1469–77.PubMedCrossRef
47.
Mehta N, Heimbach J, Harnois DM, et al. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) score for hepatocellular carcinoma recurrence After Liver Transplant. JAMA Oncol. 2017;3(4):493–500.PubMedPubMedCentralCrossRef
48.•
Tran BV, Moris D, Markovic D, et al. Development and validation of a RE current L iver c A ncer Prediction S cor E (RELAPSE) following liver transplantation in patients with hepatocellular carcinoma: analysis of the us multicenter hcc transplant consortium [published online ahead of print, 2023 Apr 10]. Liver Transpl. 2023;https://​doi.​org/​10.​1097/​LVT.​0000000000000145​. Novel post-LT HCC recurrence risk score, optimized using machine learning algorithms.
49.
Tran BV, Agopian VG. Leveraging a machine-learning approach to predict recurrent hepatocellular carcinoma following liver transplantation: a step in the right direction? Liver Transpl. 2022;28(4):547–8.PubMedCrossRef
50.
Mehta N, Bhangui P, Yao FY, et al. Liver transplantation for hepatocellular carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference. Transplantation. 2020;104(6):1136–1142.
51.
Kulik L, Heimbach JK, Zaiem F, et al. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: a systematic review and meta-analysis. Hepatology. 2018;67(1):381–400.PubMedCrossRef
52.
Kwong AJ, Ghaziani TT, Yao F, Sze D, Mannalithara A, Mehta N. National trends and waitlist outcomes of locoregional therapy among liver transplant candidates with hepatocellular carcinoma in the United States. Clin Gastroenterol Hepatol. 2022;20(5):1142-1150.e4.PubMedCrossRef
53.
Agopian VG, Harlander-Locke MP, Ruiz RM, et al. Impact of pretransplant bridging locoregional therapy for patients with hepatocellular carcinoma within Milan criteria undergoing liver transplantation: analysis of 3601 patients from the US multicenter HCC transplant consortium. Ann Surg. 2017;266(3):525–35.PubMedCrossRef
54.
Mehta N, Frenette C, Tabrizian P, et al. Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) consortium. Gastroenterology. 2021;161(5):1502–12.PubMedCrossRef
55.••
Tabrizian P, Holzner ML, Mehta N, et al. Ten-year outcomes of liver transplant and downstaging for hepatocellular carcinoma. JAMA Surg. 2022;157(9):779–88. Important multicenter study analyzing 10-year post-LT outcomes in patients with HCC that were successfully downstaged.
56.
Mazzaferro V, Citterio D, Bhoori S, et al. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial [published correction appears in Lancet Oncol. 2020 Aug;21(8):e373]. Lancet Oncol. 2020;21(7):947–956.
57.
Mehta N, Dodge JL, Grab JD, Yao FY. National experience on down-staging of hepatocellular carcinoma before liver transplant: influence of tumor burden, alpha-fetoprotein, and wait time. Hepatology. 2020Mar;71(3):943–54.PubMedCrossRef
58.
Sinha J, Mehta N, Dodge JL, Poltavskiy E, Roberts J, Yao F. Are there upper limits in tumor burden for down-staging of hepatocellular carcinoma to liver transplant? Analysis All-Comers Protocol Hepatol. 2019Oct;70(4):1185–96.
59.
Bhatti ABH, Naqvi W, Khan NY, Zia HH, Dar FS, Khan ZA, Rana A. Living donor liver transplantation for advanced hepatocellular carcinoma including macrovascular invasion. J Cancer Res Clin Oncol. 2022Jan;148(1):245–53.PubMedCrossRef
60.
Lee KW, Suh SW, Choi Y, Jeong J, Yi NJ, Kim H, Yoon KC, Hong SK, Kim HS, Lee KB, Suh KS. Macrovascular invasion is not an absolute contraindication for living donor liver transplantation. Liver Transpl. 2017Jan;23(1):19–27.PubMedCrossRef
61.
Assalino M, Terraz S, Grat M, Lai Q, Vachharajani N, Gringeri E, Bongini MA, Kulik L, Tabrizian P, Agopian V, Mehta N, Brustia R, Vitali GC, Andres A, Berney T, Mazzaferro V, Compagnon P, Majno P, Cillo U, Chapman W, Zieniewicz K, Scatton O, Toso C. Liver transplantation for hepatocellular carcinoma after successful treatment of macrovascular invasion - a multi-center retrospective cohort study. Transpl Int. 2020May;33(5):567–75.PubMedCrossRef
62.
Abdelrahim M, Esmail A, Saharia A, et al. Utilization of immunotherapy for the treatment of hepatocellular carcinoma in the peri-transplant setting: transplant oncology view. Cancers (Basel). 2022;14(7):1760.PubMedCrossRef
63.
Lominadze Z, Hill K, Shaik MR, et al. Immunotherapy for hepatocellular carcinoma in the setting of liver transplantation: a review. Int J Mol Sci. 2023;24(3):2358.PubMedPubMedCentralCrossRef
64.••
Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–905. Phase 3, IMbrave150 study, which led to atezolizumab plus bevacizumab becoming 1st-line treatment for unresectable HCC.
65.
Abou-Alfa GK, Chan SL, Kudo M, et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. J Clin Oncol. 2022;40:379–379.CrossRef
66.
Tabrizian P, Florman SS, Schwartz ME. PD-1 inhibitor as bridge therapy to liver transplantation? Am J Transplant. 2021;21(5):1979–80.PubMedCrossRef
67.
Schnickel GT, Fabbri K, Hosseini M, et al. Liver transplantation for hepatocellular carcinoma following checkpoint inhibitor therapy with nivolumab. Am J Transplant. 2022;22(6):1699–704.PubMedPubMedCentralCrossRef
68.
69.
Rajendran L, Ivanics T, Claasen MP, Muaddi H, Sapisochin G. The management of post-transplantation recurrence of hepatocellular carcinoma. Clin Mol Hepatol. 2022;28(1):1–16.PubMedCrossRef
70.
Bodzin AS, Lunsford KE, Markovic D, Harlander-Locke MP, Busuttil RW, Agopian VG. Predicting mortality in patients developing recurrent hepatocellular carcinoma after liver transplantation: impact of treatment modality and recurrence characteristics. Ann Surg. 2017;266(1):118–25.PubMedCrossRef
71.
Satapathy SK, Das K, Kocak M, et al. No apparent benefit of preemptive sorafenib therapy in liver transplant recipients with advanced hepatocellular carcinoma on explant. Clin Transplant. 2018;32(5):e13246.PubMedCrossRef
72.
Aggarwal A, Te HS, Verna EC, Desai AP. A national survey of hepatocellular carcinoma surveillance practices following liver transplantation. Transplant Direct. 2020;7(1):e638 (Published 2020 Dec 8).PubMedPubMedCentralCrossRef
73.
Ho CM, Lee CH, Lee MC, et al. Survival after treatable hepatocellular carcinoma recurrence in liver recipients: a nationwide cohort analysis. Front Oncol. 2021;10:616094.PubMedPubMedCentralCrossRef
74.
Chagas AL, Felga GEG, Diniz MA, et al. Hepatocellular carcinoma recurrence after liver transplantation in a Brazilian multicenter study: clinical profile and prognostic factors of survival. Eur J Gastroenterol Hepatol. 2019;31(9):1148–56.PubMedPubMedCentralCrossRef
75.
Flecken T, Schmidt N, Hild S, et al. Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma. Hepatology. 2014;59(4):1415–26.PubMedCrossRef
76.
Rodríguez-Perálvarez M, Tsochatzis E, Naveas MC, et al. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol. 2013;59(6):1193–9.PubMedCrossRef
77.
Geissler EK, Schnitzbauer AA, Zülke C, et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial. Transplantation. 2016;100(1):116–25.PubMedCrossRef
78.
Yang Z, Wang S, Tian XY, et al. Impact of treatment modalities on patients with recurrent hepatocellular carcinoma after liver transplantation: preliminary experience. Hepatobiliary Pancreat Dis Int. 2020;19(4):365–70.PubMedCrossRef
79.
Huang J, Yan L, Wu H, Yang J, Liao M, Zeng Y. Is radiofrequency ablation applicable for recurrent hepatocellular carcinoma after liver transplantation? J Surg Res. 2016;200(1):122–30.PubMedCrossRef
80.
Jeong YH, Hwang S, Lee GD, et al. Surgical outcome of pulmonary metastasectomy for hepatocellular carcinoma recurrence in liver transplant patients. Ann Transplant. 2021;26:e930383.PubMedPubMedCentralCrossRef
81.•
Gonvers S, Tabrizian P, Melloul E, et al. Is liquid biopsy the future commutator of decision-making in liver transplantation for hepatocellular carcinoma? [published correction appears in Front Oncol. 2023 Mar 17;13:1180615]. Front Oncol. 2022;12:940473 Important review of the current state of liquid biopsy for HCC in the context of liver transplantation.
82.
Chen Z, Lin X, Chen C, et al. Analysis of preoperative circulating tumor cells for recurrence in patients with hepatocellular carcinoma after liver transplantation. Ann Transl Med. 2020;8(17):1067.PubMedPubMedCentralCrossRef
83.
Wang PX, Xu Y, Sun YF, et al. Detection of circulating tumour cells enables early recurrence prediction in hepatocellular carcinoma patients undergoing liver transplantation. Liver Int. 2021;41(3):562–73.PubMedCrossRef
84.
Court CM, Hou S, Winograd P, Segel NH, Li QW, Zhu Y, Sadeghi S, Finn RS, Ganapathy E, Song M, French SW, Naini BV, Sho S, Kaldas FM, Busuttil RW, Tomlinson JS, Tseng HR, Agopian VG. A novel multimarker assay for the phenotypic profiling of circulating tumor cells in hepatocellular carcinoma. Liver Transpl. 2018;24(7):946–60.PubMedPubMedCentralCrossRef
85.
Lee YT, Sun N, Kim M, Wang JJ, Tran BV, Zhang RY, Qi D, Zhang C, Chen PJ, Sadeghi S, Finn RS, Saab S, Han SB, Busuttil RW, Pei R, Zhu Y, Tseng HR, You S, Yang JD, Agopian VG. Circulating tumor cell-based messenger RNA scoring system for prognostication of hepatocellular carcinoma: translating tissue-based messenger RNA profiling into a noninvasive setting. Liver Transpl. 2022;28(2):200–14.PubMedCrossRef
86.
Chen VL, Xu D, Wicha MS, Lok AS, Parikh ND. utility of liquid biopsy analysis in detection of hepatocellular carcinoma, determination of prognosis, and disease monitoring: a systematic review. Clin Gastroenterol Hepatol. 2020;18(13):2879-2902.e9.PubMedPubMedCentralCrossRef
87.
Sun N, Zhang C, Lee YT, et al. HCC EV ECG score: an extracellular vesicle-based protein assay for detection of early-stage hepatocellular carcinoma. Hepatology. 2023;77(3):774–88.PubMedCrossRef
Metadata
Title
Indication of Liver Transplant for HCC: Current Status and Future Directions
Authors
Julian K. Horwitz
Vatche G. Agopian
Publication date
22-02-2024

Other articles of this Issue 1/2024

Current Hepatology Reports 1/2024 Go to the issue

ReviewPaper

TIPS for Refractory Ascites and Hepatic Hydrothorax

ReviewPaper

Precision Management of Patients with HBV Infection

Review

Secondary Sclerosing Cholangiopathies

ReviewPaper

Should Indications for Antiviral Therapy for Hepatitis B Be Broadened to Include Immune-Tolerant Patients, Inactive Carriers, or Patients in the “Gray Zone”?

ReviewPaper

Sarcopenia and Frailty in Advanced Liver Disease Patients: A Comprehensive Review

ReviewPaper

Current Management of Hepatic Encephalopathy
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits